SlideShare a Scribd company logo
1 of 12
Paragraph III ANDA Filing
BY- Harishankar Sahu
MBA PM07
IIHMR,University,Jaipur
Abbreviated New Drug Application
• An (ANDA) contains data which when submitted to FDA's Center for Drug Evaluation
and Research, provides for the review and ultimate approval of a generic drug
product.
• Once approved, an applicant may manufacture and market the generic drug product
to provide a safe, effective, low cost alternative to the world wide.
• All approved products, both innovator and generic, are listed in FDA's Approved Drug
Products with Therapeutic Equivalence Evaluations (Orange Book).
Generic Drug Approval
 In 1970 FDA established the ANDA as a
mechanism for the review and approval of generic
versions.
 Before 1978, generic product applicants were
required to submit complete safety and efficacy
through clinical trials.
 Post 1978, applicants were required to submit
published reports of such trials documenting safety
and efficacy.
Neither of these approaches was considered
3
INNOVATOR VS GENERICS
4
S.N. PARAMETERS INNOVATOR DRUG GENERIC DRUG
1. Active ingredients Same
Same
2. Safety & efficacy Same
Same
3. Quality & strength Same
Same
4. Performance and standards Same
Same
5. Costs/prescription Highly expensive
Less expensive
6. FDA inspection of
manufacturing facilities Yes
Yes
7. FDA reviews reports of
adverse reactions Yes
Yes
8. FDA reviews drug labeling Yes
No
9. Extensive research and
ANDA
CERTIFICATION
CLAUSES
PARAGR
APH
I
PARAGR
APH II
PARAGR
APH III
PARAGR
APH IV
Para I
No listed patent.
FDA may approve generics immediately, one or more applicants may enter
Para II
A Para II filing is made when the drug is already off patent.
Para III
Paragraph III Certification indicates that the generic manufacturer will stay off
market until the patents expire.
Para IV A Para IV filing for the launch of generic drug is made when the applicant
believes its product or where the applicant believes such patents are not valid or
enforceable.
ANDA has four types of submissions.
Examples of PARAGRAPH III
Tradename: TRIFERIC
Applicant: Rockwell Medical Inc
Ingredient: ferric pyrophosphate citrate
Dosage SOLUTION;IV (INFUSION)
Ingredient-type Iron
Mechanism of Action Phosphate Chelating Activity
Approval Date: Jan 23, 2015
Patent Expiration: Apr 17, 2029
Summary for NDA: 206317
1
Examples of PARAGRAPH III
Summary for NDA: 021060
2
Tradename: PRIALT
Applicant: Jazz Pharms Intl
Ingredient: ziconotide acetate
Dosage INJECTABLE
Ingredient-type ANALGESIA
Mechanism of Action N-Calcium Channel Receptor
Antagonists
Approval Date: Dec 28, 2004
Patent Expiration: Oct 1, 2024
Examples of PARAGRAPH III
Summary for NDA: 020950
3 Tradename: DUONEB
Applicant: Mylan Speclt
Ingredients albuterol sulfate; ipratropium
bromide
Dosage SOLUTION;INHALATION
Ingredient-type TREATMENT OF BRONCHOSPASM
ASSOCIATED WITH COPD
Mechanism of Action Cholinergic Antagonists
Adrenergic beta2-Agonists
Approval Date: Mar 21, 2001
Patent Expiration: Dec 28, 2021
Examples of PARAGRAPH III
Summary for NDA: 020950
4
Tradename: CIPRO XR
Applicant: Bayer Hlthcare
Ingredient: ciprofloxacin hydrochloride
Dosage TABLET, EXTENDED
RELEASE;ORA
Ingredient-type Quinolones
Mechanism of Action inhibition of the enzymes
topoisomerase II
Approval Date: Aug 28, 2003
Patent Expiration: Dec 23, 2021
Summary for NDA: 021473
REFERENCE
• http://WWW.FDA.GOV/CDER/OGD/ .
• http://www.fda.gov/newsevents/testimony/u
cm115033.htm.
• Astrazeneca v. Apotex, et. al (Fed. Cir. 2012)
Paragraph iii anda filing

More Related Content

What's hot

What's hot (20)

Drug master file
Drug master fileDrug master file
Drug master file
 
Regulatory authority of japan
Regulatory authority of japanRegulatory authority of japan
Regulatory authority of japan
 
Generic drug product development
Generic drug product developmentGeneric drug product development
Generic drug product development
 
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIAA REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
 
Anda review process
Anda review processAnda review process
Anda review process
 
Anda.ppt
Anda.pptAnda.ppt
Anda.ppt
 
Anda submission and paragraph IV certification
Anda submission and paragraph IV certificationAnda submission and paragraph IV certification
Anda submission and paragraph IV certification
 
Para i iv orange book
Para i iv orange bookPara i iv orange book
Para i iv orange book
 
Drug Master File submissions
Drug Master File submissionsDrug Master File submissions
Drug Master File submissions
 
Global Subbmission of IND, NDA, ANDA
Global Subbmission of IND, NDA, ANDA Global Subbmission of IND, NDA, ANDA
Global Subbmission of IND, NDA, ANDA
 
CTD and eCTD
CTD and eCTDCTD and eCTD
CTD and eCTD
 
Hatch Waxman Act
Hatch Waxman ActHatch Waxman Act
Hatch Waxman Act
 
ANDA filing
ANDA filingANDA filing
ANDA filing
 
ANDA regulatory approval process
ANDA regulatory approval processANDA regulatory approval process
ANDA regulatory approval process
 
Post-marketing survillance.pptx
Post-marketing survillance.pptxPost-marketing survillance.pptx
Post-marketing survillance.pptx
 
DMF -Drug Master File
DMF -Drug Master File DMF -Drug Master File
DMF -Drug Master File
 
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
 
Generic drug ppt
Generic drug pptGeneric drug ppt
Generic drug ppt
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product development
 
Orange book
Orange bookOrange book
Orange book
 

Viewers also liked

New drug application
New drug applicationNew drug application
New drug application
VKEkbote
 

Viewers also liked (9)

Copaxone story in us and india
Copaxone story in us and indiaCopaxone story in us and india
Copaxone story in us and india
 
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crastoABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
 
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
 
New drug approval ppt
New drug approval pptNew drug approval ppt
New drug approval ppt
 
Pharma regulatory affairs
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairs
 
Pharmaceutical Mergers Acquisitions in the U.S
Pharmaceutical Mergers Acquisitions in the U.SPharmaceutical Mergers Acquisitions in the U.S
Pharmaceutical Mergers Acquisitions in the U.S
 
New drug application
New drug applicationNew drug application
New drug application
 
US and EU Submission – Comparative
US and EU Submission – ComparativeUS and EU Submission – Comparative
US and EU Submission – Comparative
 
TEDx Manchester: AI & The Future of Work
TEDx Manchester: AI & The Future of WorkTEDx Manchester: AI & The Future of Work
TEDx Manchester: AI & The Future of Work
 

Similar to Paragraph iii anda filing

Global Submission ANDA.pptx
Global Submission ANDA.pptxGlobal Submission ANDA.pptx
Global Submission ANDA.pptx
Prachi Pandey
 

Similar to Paragraph iii anda filing (20)

ANDA.pptx
ANDA.pptxANDA.pptx
ANDA.pptx
 
ANDA Filling Process
ANDA Filling ProcessANDA Filling Process
ANDA Filling Process
 
Abriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingAbriviated new drug application 505(j) filling
Abriviated new drug application 505(j) filling
 
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfGLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
 
Naresh... anda ppt
Naresh... anda pptNaresh... anda ppt
Naresh... anda ppt
 
global submission of ANDA .pptx
global submission of ANDA .pptxglobal submission of ANDA .pptx
global submission of ANDA .pptx
 
Anda ppt
Anda pptAnda ppt
Anda ppt
 
guide.pdf
guide.pdfguide.pdf
guide.pdf
 
HATCH-WAXMAN ACT & AMENDMENTS SLIDESHARE
HATCH-WAXMAN ACT & AMENDMENTS SLIDESHAREHATCH-WAXMAN ACT & AMENDMENTS SLIDESHARE
HATCH-WAXMAN ACT & AMENDMENTS SLIDESHARE
 
Drug approval in US, EU & India
Drug approval in US, EU & IndiaDrug approval in US, EU & India
Drug approval in US, EU & India
 
Global Submission ANDA.pptx
Global Submission ANDA.pptxGlobal Submission ANDA.pptx
Global Submission ANDA.pptx
 
Global Submission ANDA-.pdf
Global Submission ANDA-.pdfGlobal Submission ANDA-.pdf
Global Submission ANDA-.pdf
 
Global Submission ANDA.pptx
Global Submission ANDA.pptxGlobal Submission ANDA.pptx
Global Submission ANDA.pptx
 
ANDA, IMPD & IB
ANDA, IMPD & IBANDA, IMPD & IB
ANDA, IMPD & IB
 
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
 
Hatch Waxman Act by Anamika Dey
Hatch Waxman Act by Anamika DeyHatch Waxman Act by Anamika Dey
Hatch Waxman Act by Anamika Dey
 
Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspective
 
IND INDA ANDA Application
IND INDA ANDA ApplicationIND INDA ANDA Application
IND INDA ANDA Application
 
HATCH -WAXMAN ACT
HATCH -WAXMAN ACTHATCH -WAXMAN ACT
HATCH -WAXMAN ACT
 

More from Harishankar Sahu

More from Harishankar Sahu (20)

Tax provision in India l harishankar sahu
Tax provision in India l harishankar sahuTax provision in India l harishankar sahu
Tax provision in India l harishankar sahu
 
Solid game
Solid gameSolid game
Solid game
 
SIX SIGMA "Delivering Tomorrow's Performance Today"
SIX SIGMA"Delivering Tomorrow's Performance Today" SIX SIGMA"Delivering Tomorrow's Performance Today"
SIX SIGMA "Delivering Tomorrow's Performance Today"
 
Quality Guru Philip B. Crosby’s Management Principles
Quality Guru Philip B. Crosby’sManagement PrinciplesQuality Guru Philip B. Crosby’sManagement Principles
Quality Guru Philip B. Crosby’s Management Principles
 
Quantification, Pricing and budgeting of Drug requirement
Quantification, Pricing and budgeting of Drug requirementQuantification, Pricing and budgeting of Drug requirement
Quantification, Pricing and budgeting of Drug requirement
 
Gap analysis in Access and Quality of healthcare services : Patients and Pro...
Gap analysis in Access and Quality of healthcare services :Patients and Pro...Gap analysis in Access and Quality of healthcare services :Patients and Pro...
Gap analysis in Access and Quality of healthcare services : Patients and Pro...
 
Merck india
Merck indiaMerck india
Merck india
 
Pfizer Financial Ratio 2014
Pfizer Financial Ratio 2014Pfizer Financial Ratio 2014
Pfizer Financial Ratio 2014
 
Basics of Six Sigma
Basics of Six SigmaBasics of Six Sigma
Basics of Six Sigma
 
Tqm implementation in textile manufacturing industry to success
Tqm implementation in textile manufacturing industry to successTqm implementation in textile manufacturing industry to success
Tqm implementation in textile manufacturing industry to success
 
Collaborative Planning, Forecasting And Replenishment
Collaborative Planning, Forecasting And Replenishment Collaborative Planning, Forecasting And Replenishment
Collaborative Planning, Forecasting And Replenishment
 
Ending the war between sales and marketing marketing
Ending the war between sales and marketing marketingEnding the war between sales and marketing marketing
Ending the war between sales and marketing marketing
 
Framework of IP Administration
Framework of IP AdministrationFramework of IP Administration
Framework of IP Administration
 
Market effectiveness of revital a case study
Market effectiveness of revital a case studyMarket effectiveness of revital a case study
Market effectiveness of revital a case study
 
Marketing effectiveness
Marketing effectivenessMarketing effectiveness
Marketing effectiveness
 
Steroids
Steroids Steroids
Steroids
 
Dr sarwpalli radha krishnana ji
Dr sarwpalli radha krishnana jiDr sarwpalli radha krishnana ji
Dr sarwpalli radha krishnana ji
 
OTC DRUGS DERMATOLOGICAL
OTC DRUGSDERMATOLOGICALOTC DRUGSDERMATOLOGICAL
OTC DRUGS DERMATOLOGICAL
 
Ich – quality guidelines
Ich – quality guidelinesIch – quality guidelines
Ich – quality guidelines
 
Pharmaceutical dosage forms
Pharmaceutical dosage formsPharmaceutical dosage forms
Pharmaceutical dosage forms
 

Recently uploaded

會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
中 央社
 
Financial Accounting IFRS, 3rd Edition-dikompresi.pdf
Financial Accounting IFRS, 3rd Edition-dikompresi.pdfFinancial Accounting IFRS, 3rd Edition-dikompresi.pdf
Financial Accounting IFRS, 3rd Edition-dikompresi.pdf
MinawBelay
 
SURVEY I created for uni project research
SURVEY I created for uni project researchSURVEY I created for uni project research
SURVEY I created for uni project research
CaitlinCummins3
 

Recently uploaded (20)

PSYPACT- Practicing Over State Lines May 2024.pptx
PSYPACT- Practicing Over State Lines May 2024.pptxPSYPACT- Practicing Over State Lines May 2024.pptx
PSYPACT- Practicing Over State Lines May 2024.pptx
 
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
 
II BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING II
II BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING IIII BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING II
II BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING II
 
demyelinated disorder: multiple sclerosis.pptx
demyelinated disorder: multiple sclerosis.pptxdemyelinated disorder: multiple sclerosis.pptx
demyelinated disorder: multiple sclerosis.pptx
 
Word Stress rules esl .pptx
Word Stress rules esl               .pptxWord Stress rules esl               .pptx
Word Stress rules esl .pptx
 
The Last Leaf, a short story by O. Henry
The Last Leaf, a short story by O. HenryThe Last Leaf, a short story by O. Henry
The Last Leaf, a short story by O. Henry
 
Championnat de France de Tennis de table/
Championnat de France de Tennis de table/Championnat de France de Tennis de table/
Championnat de France de Tennis de table/
 
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
 
MOOD STABLIZERS DRUGS.pptx
MOOD     STABLIZERS           DRUGS.pptxMOOD     STABLIZERS           DRUGS.pptx
MOOD STABLIZERS DRUGS.pptx
 
An Overview of the Odoo 17 Discuss App.pptx
An Overview of the Odoo 17 Discuss App.pptxAn Overview of the Odoo 17 Discuss App.pptx
An Overview of the Odoo 17 Discuss App.pptx
 
UChicago CMSC 23320 - The Best Commit Messages of 2024
UChicago CMSC 23320 - The Best Commit Messages of 2024UChicago CMSC 23320 - The Best Commit Messages of 2024
UChicago CMSC 23320 - The Best Commit Messages of 2024
 
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjj
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjjStl Algorithms in C++ jjjjjjjjjjjjjjjjjj
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjj
 
Financial Accounting IFRS, 3rd Edition-dikompresi.pdf
Financial Accounting IFRS, 3rd Edition-dikompresi.pdfFinancial Accounting IFRS, 3rd Edition-dikompresi.pdf
Financial Accounting IFRS, 3rd Edition-dikompresi.pdf
 
An overview of the various scriptures in Hinduism
An overview of the various scriptures in HinduismAn overview of the various scriptures in Hinduism
An overview of the various scriptures in Hinduism
 
IPL Online Quiz by Pragya; Question Set.
IPL Online Quiz by Pragya; Question Set.IPL Online Quiz by Pragya; Question Set.
IPL Online Quiz by Pragya; Question Set.
 
Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17
Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17
Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17
 
Mattingly "AI and Prompt Design: LLMs with Text Classification and Open Source"
Mattingly "AI and Prompt Design: LLMs with Text Classification and Open Source"Mattingly "AI and Prompt Design: LLMs with Text Classification and Open Source"
Mattingly "AI and Prompt Design: LLMs with Text Classification and Open Source"
 
How to Manage Closest Location in Odoo 17 Inventory
How to Manage Closest Location in Odoo 17 InventoryHow to Manage Closest Location in Odoo 17 Inventory
How to Manage Closest Location in Odoo 17 Inventory
 
SURVEY I created for uni project research
SURVEY I created for uni project researchSURVEY I created for uni project research
SURVEY I created for uni project research
 
Envelope of Discrepancy in Orthodontics: Enhancing Precision in Treatment
 Envelope of Discrepancy in Orthodontics: Enhancing Precision in Treatment Envelope of Discrepancy in Orthodontics: Enhancing Precision in Treatment
Envelope of Discrepancy in Orthodontics: Enhancing Precision in Treatment
 

Paragraph iii anda filing

  • 1. Paragraph III ANDA Filing BY- Harishankar Sahu MBA PM07 IIHMR,University,Jaipur
  • 2. Abbreviated New Drug Application • An (ANDA) contains data which when submitted to FDA's Center for Drug Evaluation and Research, provides for the review and ultimate approval of a generic drug product. • Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the world wide. • All approved products, both innovator and generic, are listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
  • 3. Generic Drug Approval  In 1970 FDA established the ANDA as a mechanism for the review and approval of generic versions.  Before 1978, generic product applicants were required to submit complete safety and efficacy through clinical trials.  Post 1978, applicants were required to submit published reports of such trials documenting safety and efficacy. Neither of these approaches was considered 3
  • 4. INNOVATOR VS GENERICS 4 S.N. PARAMETERS INNOVATOR DRUG GENERIC DRUG 1. Active ingredients Same Same 2. Safety & efficacy Same Same 3. Quality & strength Same Same 4. Performance and standards Same Same 5. Costs/prescription Highly expensive Less expensive 6. FDA inspection of manufacturing facilities Yes Yes 7. FDA reviews reports of adverse reactions Yes Yes 8. FDA reviews drug labeling Yes No 9. Extensive research and
  • 6. Para I No listed patent. FDA may approve generics immediately, one or more applicants may enter Para II A Para II filing is made when the drug is already off patent. Para III Paragraph III Certification indicates that the generic manufacturer will stay off market until the patents expire. Para IV A Para IV filing for the launch of generic drug is made when the applicant believes its product or where the applicant believes such patents are not valid or enforceable. ANDA has four types of submissions.
  • 7. Examples of PARAGRAPH III Tradename: TRIFERIC Applicant: Rockwell Medical Inc Ingredient: ferric pyrophosphate citrate Dosage SOLUTION;IV (INFUSION) Ingredient-type Iron Mechanism of Action Phosphate Chelating Activity Approval Date: Jan 23, 2015 Patent Expiration: Apr 17, 2029 Summary for NDA: 206317 1
  • 8. Examples of PARAGRAPH III Summary for NDA: 021060 2 Tradename: PRIALT Applicant: Jazz Pharms Intl Ingredient: ziconotide acetate Dosage INJECTABLE Ingredient-type ANALGESIA Mechanism of Action N-Calcium Channel Receptor Antagonists Approval Date: Dec 28, 2004 Patent Expiration: Oct 1, 2024
  • 9. Examples of PARAGRAPH III Summary for NDA: 020950 3 Tradename: DUONEB Applicant: Mylan Speclt Ingredients albuterol sulfate; ipratropium bromide Dosage SOLUTION;INHALATION Ingredient-type TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD Mechanism of Action Cholinergic Antagonists Adrenergic beta2-Agonists Approval Date: Mar 21, 2001 Patent Expiration: Dec 28, 2021
  • 10. Examples of PARAGRAPH III Summary for NDA: 020950 4 Tradename: CIPRO XR Applicant: Bayer Hlthcare Ingredient: ciprofloxacin hydrochloride Dosage TABLET, EXTENDED RELEASE;ORA Ingredient-type Quinolones Mechanism of Action inhibition of the enzymes topoisomerase II Approval Date: Aug 28, 2003 Patent Expiration: Dec 23, 2021 Summary for NDA: 021473
  • 11. REFERENCE • http://WWW.FDA.GOV/CDER/OGD/ . • http://www.fda.gov/newsevents/testimony/u cm115033.htm. • Astrazeneca v. Apotex, et. al (Fed. Cir. 2012)